Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys

The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4–6 hours, and can be associated with infusion-related reactions...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Cheng-Ping, Brovarney, Martin R., Dabbagh, Karim, Birnböck, Herbert F., Richter, Wolfgang F., Del Nagro, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827219/
https://www.ncbi.nlm.nih.gov/pubmed/24265828
http://dx.doi.org/10.1371/journal.pone.0080533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827219/
https://www.ncbi.nlm.nih.gov/pubmed/24265828
http://dx.doi.org/10.1371/journal.pone.0080533

Ejemplares similares